Travelers over 60 advised to seek safer //vaccination alternatives . Individuals aged 60 and above are now being urged not to ...

Valneva SE is a specialty vaccine company that ... It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The vaccine's maker, Valneva, said in a statement that it is ... "Thorough evaluation of these cases is critical to ensure the safe use of Ixchiq," the company said. French drug regulators ...

Federal health officials are advising Americans aged 60 and older to avoid the chikungunya vaccine Ixchiq amid an investigation into potential side effects, including neurological and cardiac symptoms ...